Sign inJoin waitlistJoin the waitlist

Ana Garrido-Castro

Director, Triple-Negative Breast Cancer Research · Mass General Brigham

Credentials: · ·

History

Triple-Negative Breast Cancer Research · Mass General Brigham
Present
Mass General Brigham
Present

Medical Oncology
2020–2022
Hospital Universitario Vall d’Hebron
2017–2020
Facultad de Medicina
2006–2010

Research

Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment
Review · Cancer Discovery · 2019 · First of 3 authors · 1,142 citations
Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis
Systematic review or meta-analysis · JAMA Oncology · 2018 · 880 citations
Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer
Clinical Cancer Research · 2020 · 150 citations

Sara Tolaney
35 papers
Nancy Lin
27 papers
Elizabeth Mittendorf
17 papers
Eric Winer
13 papers
PT
Paolo Tarantino
12 papers
Tari King
12 papers
Deborah Dillon
10 papers
Filipa Lynce
9 papers
Brittany Bychkovsky
8 papers
BJ
Bruce Johnson
8 papers
IK
Ian Krop
8 papers
SM
Stefania Morganti
7 papers · 3 as a resident

Clinical trials

TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
Principal investigator · Recruiting · Phase 2
Ana C Garrido-Castro, MD
2024–2038
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
Principal investigator · Recruiting · Phase 1
National Cancer Institute (NCI)
2023–2027
Implantable Microdevice for TNBC - Pilot Study
Principal investigator · Withdrawn · Phase 1
Dana-Farber Cancer Institute
2023–2028
Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC
Principal investigator · Active not recruiting · Phase 2
Ana C Garrido-Castro, MD
2020–2027